A new cross-Canada study has found that breast and prostate cancer treatment can foster bone loss. In the online edition of the Journal of Clinical Oncology, the scientists explain how loss of bone mass might affect 46,000 people diagnosed with breast and prostate cancer each year* and place them at increased risk for osteoporosis and fractures.
"Our study also looked at possible medications that can reverse or halt bone loss," says Dr. Fred Saad, lead author and director of urologic oncology at the Université de Montréal's Faculty of Medicine and the Centre Hospitalier de l'Université de Montréal (CHUM), who completed the exhaustive study with colleagues from McMaster University, the Université Laval, the University of Toronto and the University of British Columbia.
"Bone is a dynamic tissue which undergoes a cyclic process of breaking down and rebuilding," adds Dr. Saad. "Medications called bisphosphonates help with the rebuilding process and have been successfully used to combat osteoporosis, which is good news for cancer patients."
Evaluating the studies
Dr. Saad and colleagues evaluated data from more than 3,500 breast and prostate cancer studies. They concluded that breast cancer patients treated with aromatase inhibitors were more likely to have bone loss and fractures compared to patients who didn't receive the therapy. Similarly, men who received androgen deprivation therapy to treat their prostate cancer had an increased risk of bone disorders. Although the numbers vary from one study to the next (from five to 45 percent), an elevated risk is consistently observed.
"Awareness of the incidence of cancer-associated bone loss raises issues for clinicians who should identify those patients who are most at risk for fractures and prescribe treatment strategies," says Dr. Saad. "This information is not only a concern for the specialists, but also for the general practitioners who frequently encounter these patients."
Bisphosphonate treatment reduces bone loss
Dr. Saad's group also evaluated data that included bisphosphonate treatment for cancer patients receiving chemotherapy. Prostate cancer patients who received bisphosphonate treatment and androgen deprivation therapy did show an increase in bone loss. In the same vane, there was a protective effect on bone loss for breast cancer patients who were treated with bisphosphonates.
"It is clear that the use of bisphosphonates attenuates bone loss," concludes Dr. Saad. "However, the optimal dosing and long-term impact is unclear and needs to be determined. Other measures to combat the bone loss, such as exercise, vitamin D intake, avoidance of cigarettes, may also be beneficial
*(Re: Canadian Cancer Society)
About the study:
The article "Cancer Treatment–Induced Bone Loss in Breast and Prostate Cancer" (www.jco.ascopubs.org/cgi/reprint/JCO.2008.18.4184v1), published in the American Society of Clinical Oncology, was authored by Fred Saad from the Université de Montréal and the Centre hospitalier de l'Université de Montréal; Jonathan D. Adachi of McMaster University; Jacques P. Brown of the Université Laval; Leah A. Canning and Karen A. Gelmon of the University of British Columbia; Robert G. Josse and Kathleen I. Pritchard of the University of Toronto.
Sylvain-Jacques Desjardins | EurekAlert!
The Great Unknown: Risk-Taking Behavior in Adolescents
19.01.2017 | Max-Planck-Institut für Bildungsforschung
A sudden drop in outdoor temperature increases the risk of respiratory infections
11.01.2017 | University of Gothenburg
An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...
Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...
Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.
While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...
Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales
Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...
Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.
As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...
19.01.2017 | Event News
10.01.2017 | Event News
09.01.2017 | Event News
20.01.2017 | Awards Funding
20.01.2017 | Materials Sciences
20.01.2017 | Life Sciences